Pathogenic antibodies are active participants in spinal cord injury

Journal of Clinical Investigation

Volumn 119, Issue 10, 2009, Pages 2881-2884

  Dekaban, Gregory A ^a   Thawer, Sakina ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; IMMUNOGLOBULIN;

ABSENCE OF SIDE EFFECTS; ANTIBODY PRODUCTION; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG BINDING; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; NEUROPROTECTION; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; SPINAL CORD INJURY; SPINAL CORD LESION;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; MICE, KNOCKOUT; NERVE REGENERATION; PROGNOSIS; SPINAL CORD INJURIES;

EID: 70349690269     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40839     Document Type: Note

References (20)

1. Rossignol, S., Schwab, M., Schwartz, M., and Fehlings, M.G. 2007. Spinal cord injury: time to move? J. Neurosci. 27:11782-11792. (Pubitemid 350072087)
2. Popovich, P.G., and Longbrake, E.E. 2008. Can the immune system be harnessed to repair the CNS? Nat. Rev. Neurosci. 9:481-493.
3. Riegger, T., et al. 2009. Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience. 158:1194-1199.
4. Rosas-Ballina, M., and Tracey, K.J. 2009. Cholinergic control of inflammation. J. Intern. Med. 265:663-679.
5. Lu, J., et al. 2009. Systemic inflammatory response following acute traumatic brain injury. Front. Biosci. 14:3795-3813.
6. Ankeny, D.P., Guan, Z., and Popovich, P.G. 2009. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J. Clin. Invest. 119:2990-2999.
7. Dalakas, M.C. 2008. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4:557-567.
8. Dalakas, M.C. 2008. Invited article: inhibition of B cell functions: implications for neurology. Neurology. 70:2252-2260.
9. Corcione, A., et al. 2004. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 101:11064-11069. (Pubitemid 38989584)
10. Waubant, E. 2008. Spotlight on anti-CD20. Int. MS J. 15:19-25.
11. Elkon, K., and Casali, P. 2008. Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4:491-498.
12. Matsushita, T., and Tedder, T.F. 2009. B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting. Expert Rev. Neurother. 9:309-312.
13. Lucin, K.M., Sanders, V.M., Jones, T.B., Malarkey, W.B., and Popovich, P.G. 2007. Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp. Neurol. 207:75-84.
14. Kwidzinski, E., and Bechmann, I. 2007. IDO expression in the brain: a double-edged sword. J. Mol. Med. 85:1351-1359. (Pubitemid 350234090)
15. Oxenkrug, G.F. 2007. Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann. N. Y. Acad. Sci. 1122:35-49.
16. Kwidzinski, E., et al. 2005. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19:1347-1349. (Pubitemid 41113745)
17. Xu, H., Zhang, G.X., Ciric, B., and Rostami, A. 2008. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol. Lett. 121:1-6.
18. Mellor, A.L., and Munn, D.H. 2008. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8:74-80.
19. Scott, G.N., et al. 2009. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol. 182:7509-7517.
20. Gold, R., Stangel, M., and Dalakas, M.C. 2007. Drug insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3:36-44. (Pubitemid 46056032)